Results Validate In Vivo Liver DNA Base Editing as a Once-and-Done Approach to Treat Coronary Heart Disease by Lowering of LDL Cholesterol and PCSK9 Protein Levels CAMBRIDGE, Mass.--(BUSINESS ...

DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Last week, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), leading epigenetic editing company Tune Therapeutics showcased ...

Eli Lilly and Company is acquiring Verve Therapeutics, Inc. for $1B upfront plus a $3/share CVR upon milestone being met, driven by promising gene-editing therapies for ASCVD. VERVE-102, a one-time IV ...

PHILADELPHIA, PA—For high-risk patients with heterozygous familial hypercholesterolemia (HeFH), a novel therapy that shuts off the PCSK9 gene can lower LDL cholesterol, early data from the heart-1 ...

BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene ...

Verve Therapeutics aims to revolutionize cardiovascular disease treatment with single-course gene editing, despite facing significant challenges and setbacks in clinical trials. The company's lead ...

Because identical twins develop from a single fertilized egg, they have the same genome, the entire set of genetic material found in an organism. So, any differences between them, even in traits with ...

In a recent study published in the journal Nature, scientists used mouse models to test whether in vivo gene silencing is sustained after transient delivery and expression of engineered ...

One of the main goals in the prevention of cardiovascular disorders is to maintain low-density lipoprotein cholesterol (LDL-C) at consistently low levels to ensure long-term cardiovascular protection.

Precision BioSciences was founded in 2006 to develop a genome editing technology that uses homing nucleases to make precise edits in DNA. Now, the company has preclinical evidence showing that the ...